After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million). | After nearly nine years ...
Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise ...
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...
When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...
Emma Walmsley has served as CEO of GlaxoSmithKline since 2017. From the Philadelphia Business Journal. GSK is making a change at the top. The London-based Big Pharma company, which has major ...
GSK on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing ...
"After you take some well-deserved time off … let's do it again!" the chair of RAPT Therapeutics' board tells co-founder-CEO ...
GSK will buy Canadian biotech 35Pharma for $950 million to gain HS235, a promising pulmonary hypertension treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results